Rhythm Pharmaceuticals, Inc.RYTMNASDAQ
LOADING
|||
RYTM Revenue Growth (YoY Quarterly)•+54.28%
SAPRO
Growth Metrics
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +47.76% | +72.61% | +25.94% | +66.80% | +54.28% |
| Gross Profit Growth | +46.44% | +81.15% | +25.46% | +64.40% | +55.66% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +5.78% | +4.03% | +4.85% | +4.38% | +5.11% |
| Weighted Average Shares Diluted Growth | +5.78% | +4.03% | +4.85% | +4.38% | +5.11% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +32.77% | +24.52% | +21.30% | +48.44% | +71.11% |
| Inventory Growth | +79.01% | +117.31% | +127.06% | +57.35% | -100.00% |
| Asset Growth | +2.65% | +17.89% | +49.50% | -2.39% | +39.42% |
| Book Value per Share Growth | -26.90% | -6.82% | +152.59% | +0.00% | -7.28% |
| Debt Growth | +179.86% | +212.54% | +277.25% | +6202.50% | +3647.02% |
| R&D Expense Growth | +12.99% | +37.72% | -71.22% | +40.95% | +21.34% |
| SG&A Expenses Growth | +16.09% | +17.78% | +13.68% | +26.18% | +48.19% |
1 / 4